Industry
Nyah Brandon
2026-04-23
Primary Keywords
| Number | Publication Title | Link | Count |
|---|---|---|---|
| NXC-201-AL-001 | Phase 1b/2 Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis (NEXICART-2) | NULL | 1 |
| IM048022 | A Phase III Two-stage Randomized Multi-center Controlled Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) | NULL | 2 |
| CA057-001 | A Phase III Two-Stage Randomized Multicenter Open-Label Study Comparing Mezigdomide (CC-92480) Bortezomib And Dexamethasone (MEZIVd) Versus Pomalidomide Bortezomib And Dexamethasone (PVd) In Subjects With Relapsed Or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1 | NULL | 2 |
| OPN6602-C01 | A Phase Ib Dose Escalation/Dose Expansion Multicenter Open-Label Study to Assess the Safety and Tolerability of OPN-6602 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma | NULL | 1 |
| MRKR-22-601-01 (APOLLO) | A Phase I Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T-Cells (MT-601) Administered to Patients with Relapsed or refractory Non-Hodgkin Lymphoma (NHL [APOLLO]) | NULL | 2 |
| MRKR-21-401-OTS | A Phase I Study of Allogeneic Off-the-Shelf Multi-Tumor-Associated Antigen-Specific T Cell Products (MT-401-OTS) Administered to Patients With Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndromes (RAPID) | NULL | 2 |
| MK3475-975 | A Randomized Double-blind Placebo-controlled Phase III Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants with Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) | NULL | 1 |
| RMC-GI-102 Subprotocol E | Study of RMC-9805 with or without RMC-6236 in Combination with Cetuximab-based Therapies in Patients with RAS G12D-Mutant Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma � Subprotocol E | NULL | 5 |
| D7987C0001 GEMINI | A Phase II Open-Label Multi-Drug Multi-Centre Master Protocol to Evaluate the Efficacy and Safety of Novel Bispecific Antibodies as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Hepatobiliary Cancer (D7987C00001) GEMINI | NULL | 1 |
| TYR430-101 | A Multicenter Open-Label First-in-Human Study of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors with Activating FGF/FGFR pathway alterations (SURF431) | NULL | 2 |
| RMC-GI-102 Core | A Platform Study of RAS(ON) Inhibitors to Treat Patients with Gastrointestinal Solid Tumors | NULL | 1 |
| TT420C2308 | A Phase III Randomized Controlled Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician�s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308) | NULL | 2 |
| CHS-388-202 | A Randomized Phase II Study of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | NULL | 2 |
| 1438-0005 DAREON-5 | DAREON�-5: An open-label multi-center Phase II dose selection trial of intravenous BI 764532 a DLL3 targeting T cell engager in patients with relapsed/refractory extensive-stage small cell lung cancer and in patients with other relapsed/refractory neuroendocrine carcinomas | NULL | 3 |
| STAR-101 | A Phase I Study of SynKIR-110 Autologous T cells Transduced with Mesothelin KIR-CAR in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer Cholangiocarcinoma or Mesothelioma | NULL | 3 |
| LTFU 101-00 | A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product | NULL | 1 |
| NRG-CC005 | FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps) | NULL | 1 |
| NT-112-301 | An Open-label Phase 1 Multi-Center Master Protocol to Evaluate the Safety and Preliminary Anti-Tumor Activity of TCR-engineered T cells Recognizing KRAS Mutations in Adult Subjects with Unresectable Advanced and/or Metastatic Solid Tumors | NULL | 4 |
| TCD17620 | A Phase I/Ib Open Label First-In-Human Study Dose Escalation And Expansion Study For The Evaluation Of Safety Pharmacokinetics Pharmacodynamics And Anti-Tumor Activity Of SAR445877 Administered As Monotherapy Or In Combination With An Anti PD L1 Therapy In Adults With Advanced Solid Tumors (The �Study�) | NULL | 2 |
| ZZ06-2020A | A Phase I Multicenter Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics Immunogenicity and Preliminary Evidence of Antitumor Activity of ZZ06 in Adult Patients with Advanced Solid Tumor Malignancies | NULL | 2 |
| RP1-104 | A Randomized Controlled Multicenter Phase III Clinical Study Comparing Vusolimogene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician�s Choice in Patients with Advanced Melanoma That Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen | NULL | 1 |
| IMCgp100-203 | Phase II/III Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator�s Choice in HLAA*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM) | NULL | 1 |
| IMC-F106-C-301 | A Phase III Randomized Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) | NULL | 1 |
| R3767-ONC-22122 | A PHASE III STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA | NULL | 2 |
| ERAS-254-02 | A Randomized Open-Label Phase III Study in Patients with Previously Treated Unresectable or Metastatic NRAs Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician’s Choice of Therapy (Dacarbazine Temozolomide or Trametinib Monotherapy) with a Dose Optimization Lead-In (SEACRAFT-2) | NULL | 2 |
| DARES | A Phase II Trial of Durvalumab (MEDI4736) and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer (DARES) | NULL | 3 |
| GLB-001-01 | A First-in-Human (FIH) Phase 1 Multicenter Open-label Dose Escalation and Expansion Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of Orally Administered GLB-001 in Patients with Refractory or Relapsed Acute Myeloid Leukemia (R/R AML) or Refractory or Relapsed Higher-risk Myelodysplastic Syndromes (R/R HR-MDS) | NULL | 1 |
| CA073-1003 | A Phase III Multicenter Randomized Open Label Study to Compare the Efficacy and Safety of Golcadomide in Combination with Rituximab (Golca + R) Vs Investigator�s Choice in Participants with Relapsed/Refractory Follicular Lymphoma who have Received at least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | NULL | 1 |
| CA073-1020 | A Phase III Multicenter Randomized Double-blind Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) | NULL | 3 |
| CC-220-DLBCL-001 | A Phase Ib Open Label Global Multicenter Dose Determination Randomized Dose Expansion Study To Determine The Maximum Tolerated Dose Assess The Safety And Tolerability Pharmacokinetics And Preliminary Efficacy Of Iberdomide (CC-220) In Combination With R-CHOP21 And CC-99282 In Combination With R-CHOP21 For Subjects With Previously Untreated Poor Risk (IPI 3-5) Aggressive B-Cell Lymphoma | NULL | 1 |
| BGB-11417-108 | A Phase 1/2 Open-label Study to Investigate the Safety of Sonrotoclax Ramp-up Schedule(s) in Adult Patients With Hematological Malignancies. | NULL | 1 |
| BGB-16673-104 | A Phase 1b/2 Open-Label Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies | NULL | 1 |
| RLY-2608-102 | A Phase III Open-label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment with a CDK4/6 Inhibitor | NULL | 3 |
| CAAA603B12101 | A phase Ib dose finding study assessing safety and activity of (177Lu)Lu-NeoB in combination with ribociclib and fulvestrant in participants with ER+ HER2- and GRPR-positive advanced breast cancer experiencing early relapse from (neo)adjuvant endocrine therapy or have progressed on endocrine therapy in combination with a CDK4 /6 inhibitor for advanced disease | NULL | 2 |
| RMC-6236-301 | RASolve 301: Phase 3 Multicenter Open Label Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS(MUT) NSCLC | NULL | 1 |
| M23-721 | Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Evaluation of the Optimal Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy � LIVIGNO-4 | NULL | 5 |
| SMT112-3003 | A Randomized Double-blind Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer(HARMONi-3) | NULL | 5 |
| 61186372NSC2002 | A Phase II Open-Label Parallel Cohort Study Of Subcutaneous Amivantamab In Multiple Regimens In Patients With Advanced Or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer (PALOMA-2) | NULL | 5 |
| 61186372NSC2012 (COPERNICUS) | A Phase IIb Open-Label Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer COPERNICUS | NULL | 4 |
| J3M-MC-JZQB SUNRAY-01 | SUNRAY-01 A Global Pivotal Study in Participants with KRAS G12C-Mutant Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ?50% or LY3537982 and Pembrolizumab Pemetrexed Platinum vs Placebo and Pembrolizumab Pemetrexed Platinum regardless of PD-L1 Expression | NULL | 3 |
| EF-44 | LUNAR-2: Pivotal Randomized Open-Label Study of Tumor Treating Fields (TTFields 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer | NULL | 5 |
| SGNB6A-001 | A Phase 1 Study of SGN-B6A-001 in Advanced Solid Tumors | NULL | 1 |
| R4018-ONC-2445 | Multi-arm Phase II Study OF Ubamatamab (REGN4018; MUC16�CD3 Bispecific Antibody) With or Without Additional Agents in Platinum-resistant Ovarian Cancer | NULL | 1 |
| GCT1184-02 | A Phase III Randomized Open-label Study of Rinatabart Sesutecan (Rina-S) versus Treatment of Investigator�s Choice (IC) in Patients with Platinum Resistant Ovarian Cancer | NULL | 1 |
| GOG-3068/HOTT | A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Homologous Recombinant Deficient (HRD +) Newly Diagnosed Stage III and IV Ovarian Primary Peritoneal and Fallopian Tube Cancer (Hyperthermic Ovarian Treatment Trial) | NULL | 2 |
| PRO1184-001 | Phase 1/2 Study of Rina-S in Patients with Locally Advanced and/or Metastatic Solid Tumors | NULL | 2 |
| 222730 | A Phase I Clinical Study to Evaluate the Safety Tolerability Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Subjects with Advanced Solid Tumors | NULL | 1 |
| IIT-2023-SIGNA / CO-US-576-6606 | A Phase II Open-Label Study of Sacituzumab Govitecan in Patients with Previously Treated Locally Advanced Recurrent or Metastatic Cholangiocarcinoma | NULL | 2 |
| YL217-INT-101-01 | A Phase I Multicenter Open-Label First-in-Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of YL217 in Patients with Advanced Solid Tumors | NULL | 1 |
| 3082-CL-0101 | Phase I Study in Metastatic Solid Tumor Malignancies with KRAS G12D Mutation (ASP3082) (Parexel 267236) | NULL | 4 |
| NP-G2-044-P2-01 | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NULL | 3 |
| IIT-2024-PANCONVA | A Phase Ib/II trial of Onvansertib in Combination with NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer | NULL | 1 |
| 8951-CL-0305 | A Phase 3 Double-blind Randomized Study of Zolbetuximab in Combination with Pembrolizumab and Chemotherapy (CAPOX or mFOLFOX6) in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma in Participants Whose Tumors are HER2-negative Claudin (CLDN) 18.2-positive and Programmed Death-ligand 1 (PD-L1)-positive | NULL | 4 |
| Astellas 2138-CL-0101 | A Phase I/Ib Study of ASP2138 in Participants with Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumor Have Claudin (CLDN) 18.2 Expression | NULL | 5 |
| CA0711000 | A Phase III Two-part Randomized Open-label Adaptive Study Comparing BMS-986365 versus Investigator�s Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI) in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | NULL | 3 |
| KO-MEN-008 | Phase I Study to Determine the Safety and Tolerability of Ziftomenib Combinations for the Treatment of KMT2A-rearranged or NPM1-mutant Relapsed/Refractory Acute Myeloid Leukemia | NULL | 1 |
| APVO436-5201 | A Phase Ib/II Open-Label Study of APVO436 in Combination with Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) | NULL | 1 |
| MM1YA-S01 | A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs (Daunorubicin and Cytarabine) Liposome Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by MYELOMATCH; A MYELOMATCH CLINICAL TRIAL | NULL | 3 |
| BAML-16-001-S17 | A Phase Ib Dose Escalation and Expansion Study of SNDX-5613 Azacitidine and Venetoclax in Newly Diagnosed Untreated Acute Myeloid Leukemia (AML) Patients ? 60 years with NPM1 Mutated/FLT3-ITD and FLT3-TKD Wild Type AML or Mixed Lineage Leukemia (MLL) Gene Rearrangements | NULL | 2 |
| BAML-16-001-M1 | A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) | NULL | 1 |
| BAML-16-001-S21 | A Phase 1 Open-label Dose Escalation and Dose Expansion Multicenter Clinical Trial to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) | NULL | 1 |
| LBS-007-CT01 | A Phase I/II Open-label Dose Escalation and Expansion Study to Evaluate the Safety and Tolerability of LBS-007 in Patients with Relapsed or Resistant Acute Leukemia | NULL | 1 |
| MYELOMATCH | Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials | NULL | 1 |
| KO-MEN-007 | Phase I study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia | NULL | 2 |
| PMB-102 | A Phase I Study Evaluating BAFFR-targeting CAR T cells for Patients with Relapsed or Refractory B-cell Non-Hodgkin�s Lymphoma (B-NHL) | NULL | 2 |
| Celestial-301 | A Phase 1 Study of SynKIR-310 Autologous T cells Transduced with CD19 KIR-CAR in Participants with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | NULL | 1 |
| CRSP-ONC-006 | A Phase I/II Open-Label Multicenter Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9�Engineered T Cells (CTX112) in Subjects With Relapsed or Refractory B Cell Malignancies | NULL | 1 |
| CRSP-ONC-LTF | A Long-term Follow-up Study of Subjects With Malignancies Treated With CRISPR CAR Cellular Therapies | NULL | 1 |
| CCTL019A2205B | Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 directed CART Cell Therapy | NULL | 1 |
| IIT-2018-Gamma-Delta-Tcell | Phase I study of ex vivo expanded/activated gamma delta T-cell infusion following haploidentical hematopoietic stem cell transplantation and post-transplant cyclophosphamide | NULL | 1 |
| BMT CTN 2203 (PROGRESS IV) | A Randomized Multicenter Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (GVHD Prophy Rux) (PROGRESS IV) | NULL | 1 |
| BCA101X301 | A Multicenter Randomized Double-Blind Phase II/III Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | NULL | 2 |
| FMC-376-CL101 | An Open-label Phase I/II Dose-Escalation Dose Expansion and Cohort Expansion Study Evaluating the Safety PK and Clinical Activity of FMC-376 in Participants with KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors (PROSPER) | NULL | 2 |
| TBBO8520-101 | A Phase 1a/1b Open-Label Study Evaluating the Safety Tolerability Pharmacokinetics and Efficacy of BBO-8520 in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer - The ONKORAS-101 Study | NULL | 2 |
| AV-299-23-301 | A Multicenter Randomized Double-blind Placebo-Controlled Phase III Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) | NULL | 3 |
| VERSATILE-003 (PDS0101-HNC-301) | A Phase III Open-Label Randomized Study of PDS0101 Plus Pembrolizumab vs Pembrolizumab Alone in First Line Treatment of Immune Checkpoint Inhibitor (ICI) Na�ve Subjects with Unresectable Recurrent and/or Metastatic (R/M) Human Papillomavirus 16 (HPV16)-Positive Head and Neck Squamous Cell Carcinoma (HNSCC) | NULL | 3 |
| D798EC00001 | A Phase III Randomized Open-Label Multi-Center Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) | NULL | 1 |
| TP-CA-006 | TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC) | NULL | 2 |
| CELC-G-302 | VIKTORIA-2: A Randomized Open-Label Phase III Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer. | NULL | 2 |
| CURCu64PSM0003 | A Phase III Multicenter Open-label Study to Test the Diagnostic Performance of Copper Cu 64 PSMA I&T PET/CT in Staging of Men with Newly Diagnosed Unfavorable Intermediate-risk High-risk or Very High-risk Prostate Cancer Electing to Undergo Radical Prostatectomy with Pelvic Lymph Node Dissection | NULL | 2 |
| CLEE011O12001 | A phase IIIb study to characterize the efficacy and safety of Adjuvant ribociclib plus endocrine therapy in a close-to-clinical practice patient population with HR+ HER2? early breast cancer (Adjuvant WIDER) | NULL | 2 |
| NRG-GU008 | Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE) INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy | NULL | 4 |
| NRG-GU010 | Parallel Phase III Randomized Trials Of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (Guidance) | NULL | 2 |
| CAAA617D12302 | An International Prospective Open-label Multi-center Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus Observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC) | NULL | 3 |
| U0755 | SpaceIT Hydrogel System for Perirectal Spacing in Subjects with Low to Intermediate Risk Prostate Cancer Undergoing External Beam Radiotherapy (EBRT): A multicenter randomized controlled clinical study (HYDROSPACE) | NULL | 3 |
| CAAA817B12301 | AcTFirst: A phase III open-label multi-center randomized study comparing AAA817+ARPI versus standard of care in adult participants with PSMA-positive metastatic castration resistant prostate cancer | NULL | 3 |
| IIT-2023-Relugolix-RT | Quantifying Optimal Relugolix Duration with Radiation in High Risk Prostate Cancer (QURE-PC) | NULL | 3 |
| BG-C477-101 | A Multicenter Open-Label Phase Ia/b First-in-Human Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors | NULL | 1 |
| BGB-53038-101 | A Phase Ia/Ib Study to Investigate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Preliminary Antitumor Activity of BGB-53038 a Pan-KRAS Inhibitor as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | NULL | 3 |
| CP-START-001 | A Phase I/II First-in-Human Open-Label Dose Escalation and Expansion Study of STAR0602 a Selective T Cell Receptor (TCR)-targeting Bifunctional Antibody-fusion Molecule in Subjects with Unresectable Locally Advanced or Metastatic Solid Tumors that are Antigen-rich (START-001) | NULL | 2 |
| SGNS70-101 | A Phase 1 Study of SEA-CD70 in Myeloid Malignancies | NULL | 1 |
| INCB 160058-101 | A Phase I Open-Label Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms | NULL | 1 |
| INCA33989-102 | A Phase 1 Open-Label Multicenter Study of INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | NULL | 1 |
| MPN-RC 122 | A Phase II study of Canakinumab in patients with Myelofibrosis Myeloproliferative Neoplasms Research Consortium | NULL | 1 |
| NXC-201-AL-002 | Phase 1b/2 Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis (NEXICART-2) | NULL | 1 |
## [1] "Frequency Table of Primary Keywords"Secondary Keywords
## [1] "Frequency Table of Secondary Keywords"| Number | Publication Title | Link | Count |
|---|---|---|---|
| BAML-16-001-M1 | A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial) | NULL | 1 |
| MYELOMATCH | Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials | NULL | 1 |
| TP-CA-006 | TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Head & Neck Squamous Cell Carcinoma (HNSCC) | NULL | 1 |
Publication Titles with No Primary or Secondary Keywords
## Number of Publications with No Primary or Secondary Keywords : 12Primary Vs. Secondary Keywords
## [1] "Publication Titles (counts = n) Classified by Primary, Secondary, Both or No Keywords"## [1] "Reviewing Publication Titles Classified by Primary, Secondary, Both or No Keywords"